
|Videos|November 11, 2013
Therapies in Development for the Treatment of Pancreatic Cancer
Author(s)Margaret A. Tempero, MD
Margaret A. Tempero, MD, discusses therapies that are currently in development for the treatment of pancreatic cancer.
Advertisement
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses therapies that are currently in development for the treatment of pancreatic cancer.
Clinical Pearls
- Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer
- Stromal depleting agents are also in development
- There is a lot of interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































